Most Read Articles
Stephen Padilla, 16 Dec 2019
Treatment with fludarabine, cytarabine and G-CSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (Ida) is associated with high remission rates among patients with newly diagnosed core binding factor acute myelogenous leukaemia (CBF-AML) with low induction mortalities, reports a study.
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Elaine Soliven, 17 Dec 2019
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves response rates and depth of response in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT), according to updated results of the phase II GRIFFIN* study presented at ASH 2019.
4 days ago
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.

Comprehensive geriatric assessment may help refine azacytidine targets in MDS

19 Jan 2020
Looking into 2018, Singapore has a few plans in mind to improve healthcare for the public, especially the elderly.

In elderly adults with myelodysplastic syndrome (MDS), the comprehensive geriatric assessment (CGA) can detect geriatric-related health issues and may be useful in identifying those unlikely to benefit from azacytidine treatment, a recent study has shown.

The researchers performed a prospective study on 98 elderly MDS patients (median age at diagnosis, 76 years; 62 males), in whom the burden of geriatric-related health issues was assessed using the CGA. The duration of azacytidine treatment and patient survival were compared between groups with vs without CGA deficits.

Majority (78 percent; n=77) of the participants had deficits in at least one CGA domain; 56 percent (n=55) and 39 percent (n=38) had deficits in two and three domains, respectively. A third (34 percent; n=33) had at least one deficit in instrumental activities of daily living (iADL), suggesting that these patients were dependent on others for tasks such as food preparation, medication and finances.

Patients who were dependent for iADLs were also found to have completed significantly fewer cycles of azacytidine (mean, 3.7±2.6 vs 12.1±7.9; p=0.005). Those with cognitive impairment (3.5±2.1 vs 10.9±7.9; p=0.034) and abnormal Timed Get Up and Go results (3.8±2.5 vs 13.2±7.8; p=0.001) likewise completed a significantly lower number of azacytidine cycles.

In turn, this led to worse survival outcomes. Patients who were unable to complete six cycles of azacytidine treatment had significantly shorter median overall survival than their counterparts who had taken at least six cycles (5.5 vs 18 months; p=0.005).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 16 Dec 2019
Treatment with fludarabine, cytarabine and G-CSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (Ida) is associated with high remission rates among patients with newly diagnosed core binding factor acute myelogenous leukaemia (CBF-AML) with low induction mortalities, reports a study.
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Elaine Soliven, 17 Dec 2019
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves response rates and depth of response in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT), according to updated results of the phase II GRIFFIN* study presented at ASH 2019.
4 days ago
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.